DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Ampreloxetine

Generic Name: Ampreloxetine

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₈F_₃NO

CAS Number: 1227056-84-9

Unique Ingredient Identifier: 19997EZ42I

Overview

Ampreloxetine is under investigation in clinical trial NCT03750552 (Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure).

Background

Ampreloxetine is under investigation in clinical trial NCT03750552 (Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Phase 3

Recruiting

Posted: 2023/01/25

Sponsor:Theravance Biopharma

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Phase 1

Completed

Posted: 2020/12/30

Sponsor:Theravance Biopharma

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

Phase 1

Completed

Posted: 2019/12/16

Sponsor:Theravance Biopharma

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Phase 3

Terminated

Posted: 2019/09/19

Sponsor:Theravance Biopharma

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Phase 3

Terminated

Posted: 2019/02/04

Sponsor:Theravance Biopharma

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Ampreloxetine Shows Promise for Neurogenic Orthostatic Hypotension in MSA Patients Without Worsening Supine Hypertension

2 months ago

New analyses from Theravance Biopharma's Phase 3 trials demonstrate ampreloxetine's selective mechanism of action and durable target engagement in treating neurogenic orthostatic hypotension (nOH) in multiple system atrophy patients.

FDA Approves EGRIFTA WR™: New Weekly Reconstitution Formulation for HIV-Associated Lipodystrophy

2 months ago

Theratechnologies has received FDA approval for EGRIFTA WR™ (tesamorelin F8), a new formulation that requires weekly rather than daily reconstitution for treating excess visceral abdominal fat in adults with HIV and lipodystrophy.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy